@ChadTangMD
1/5 Our latest #MsaouelLab article in @EurUrolOncol introduces RMC-COMPASS, the first prognostic model designed specifically for patients with SMARCB1-deficient #RenalMedullaryCarcinoma: authors.elsevier.com/a/1o3ol9Cfw07G… #endRMC #MsaouelLab #rarecancers #kidneycancerView quoted post on X
Hear the latest on MDT for oligomets from the first author himself, @AlexSherryMD!View quoted post on X
Check out the paper📜 AND the podcast🎙️ for some main highlights! ☢️
📜ascopubs.org/doi/10.1200/JC…
🎙️ascopubs.org/do/jco-article…
@ChadTangMD @ebludmir
1/5 New in @EurUrolOncol: the largest series yet of metastasis-directed radiation therapy in SMARCB1-deficient #RenalMedullaryCarcinoma. Key finding that this cancer appears far more radiosensitive than clear cell kidney cancer: authors.elsevier.com/c/1n~As9Cfw07G… #endRMC #MsaouelLabView quoted post on X
🩺 The evolving role of SBRT in metastatic kidney cancer
At the 2nd Florence International Consensus, Prof. Chad Tang from @UTMDAnderson highlights how stereotactic body radiotherapy (SBRT) is becoming an increasingly important part of metastatic renal cell carcinoma (RCC) management. #FlorenceConsensus26
🎯 Oligometastatic disease SBRT may help defer systemic therapy and its associated side effects in selected patients. Local treatment approaches—including radiotherapy, surgery and interventional ablation—offer options that work through mechanisms distinct from systemic therapy.
🔬 Oligoprogressive disease By targeting a limited number of progressing lesions, SBRT may allow patients to remain on their current systemic treatment for longer, potentially delaying the need to switch to subsequent lines of therapy.
💡 The key takeaway: Across the metastatic disease spectrum, SBRT is expanding the role of local treatment in kidney cancer care, supporting more tailored treatment strategies and helping clinicians consider how best to manage disease progression while preserving treatment options.
📍 As evidence and clinical experience continue to evolve, multidisciplinary decision-making remains essential to identifying the patients most likely to benefit.
#KidneyCancer
@Lucarecco @CarlottaB @RobClarkeLab @JavierCortesMD @curijoey @delmastro_lucia @ALEDIGNUS12 @Prof_Nadia_H @ClareIsacke @reshmajagsi @KaidarOrit @AnnaKirby17 @matteolambe @Icro_Meattini @hoperugo @TanjaSpanic @MassimoDiMaio75 @Silke_Gillessen @DrRanaMcKay @brian_rini @alison_tree @ChadTangMD @DrYukselUrun @MicheleAquilano @GiulioFrancoli1 @DrDanielHengView quoted post on X
